Skip to main content
Erschienen in: Der Ophthalmologe 11/2012

01.11.2012 | Leitthema

Morphologische Veränderungen durch Konservierungsmittel in Augentropfen

verfasst von: Dr. K.K. Huber-van der Velden, H. Thieme, M. Eichhorn

Erschienen in: Die Ophthalmologie | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zahlreiche experimentelle und klinische Untersuchungen der letzten Jahre haben z. T. erhebliche zytologische und histologische Veränderungen in Augengeweben nach chronischer Anwendung von Augentropfen nachgewiesen, für die nach heutigem Wissensstand die enthaltenden Konservierungsmittel verantwortlich zu machen sind. Das am häufigsten verwendete Konservierungsmittel ist Benzalkoniumchlorid (BAC), das eine verhältnismäßig hohe Zelltoxizität aufweist. Zu den möglichen Folgen der Konservierungsmittelexposition gehören chronische Entzündungen mit nachfolgender Fibrose der Subkonjunktiva sowie Zellverlust und strukturelle Veränderungen im Konjunktivaepithel wie auch im Korneaepithel und -endothel. Häufig kommt es während der Behandlung zur Verschlechterung oder zum erstmaligen Auftreten des trockenen Auges. In den letzten Jahren wurden neue Konservierungsmittel wie Polyquad, Purite® oder SofZia entwickelt, deren Nebenwirkungsprofile günstiger erscheinen. Allerdings liegen hierzu noch vergleichsweise wenig Daten vor. Wenn man die Belastungen für die Gewebe des Auges durch Augentropfen minimieren möchte, ist eine Therapie mit konservierungsfreien Präparaten anzustreben.
Literatur
1.
Zurück zum Zitat Acheampong AA, Small D, Baumgarten V et al (2002) Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther 18:325–337PubMedCrossRef Acheampong AA, Small D, Baumgarten V et al (2002) Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther 18:325–337PubMedCrossRef
2.
Zurück zum Zitat Ammar DA, Kahook MY (2011) Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 17:1806–1813PubMed Ammar DA, Kahook MY (2011) Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Mol Vis 17:1806–1813PubMed
3.
Zurück zum Zitat Ammar DA, Kahook MY (2011) Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol 95:1466–1469PubMedCrossRef Ammar DA, Kahook MY (2011) Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol 95:1466–1469PubMedCrossRef
4.
Zurück zum Zitat Ammar DA, Noecker RJ, Kahook MY (2010) Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 27:837–845PubMedCrossRef Ammar DA, Noecker RJ, Kahook MY (2010) Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 27:837–845PubMedCrossRef
5.
Zurück zum Zitat Baudouin C, Garcher C, Haouat N et al (1994) Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 101:454–460PubMed Baudouin C, Garcher C, Haouat N et al (1994) Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 101:454–460PubMed
6.
Zurück zum Zitat Baudouin C, Labbe A, Liang H et al (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29:312–334PubMedCrossRef Baudouin C, Labbe A, Liang H et al (2010) Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res 29:312–334PubMedCrossRef
7.
Zurück zum Zitat Baudouin C, Riancho L, Warnet JM et al (2007) In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 48:4123–4128PubMedCrossRef Baudouin C, Riancho L, Warnet JM et al (2007) In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci 48:4123–4128PubMedCrossRef
8.
Zurück zum Zitat Brignole-Baudouin F, Riancho L, Liang H et al (2011) Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res 36:979–988PubMedCrossRef Brignole-Baudouin F, Riancho L, Liang H et al (2011) Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res 36:979–988PubMedCrossRef
9.
Zurück zum Zitat Broadway DC, Grierson I, O’brien C et al (1994) Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 112:1437–1445PubMedCrossRef Broadway DC, Grierson I, O’brien C et al (1994) Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 112:1437–1445PubMedCrossRef
10.
Zurück zum Zitat Broadway DC, Grierson I, O’brien C et al (1994) Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 112:1446–1454PubMedCrossRef Broadway DC, Grierson I, O’brien C et al (1994) Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 112:1446–1454PubMedCrossRef
11.
Zurück zum Zitat Burstein NL (1980) Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 19:308–313PubMed Burstein NL (1980) Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 19:308–313PubMed
12.
Zurück zum Zitat De Saint Jean M, Brignole F, Bringuier AF et al (1999) Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 40:619–630 De Saint Jean M, Brignole F, Bringuier AF et al (1999) Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 40:619–630
13.
Zurück zum Zitat Debbasch C, Brignole F, Pisella PJ et al (2001) Quaternary ammoniums and other preservatives‘ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 42:642–652PubMed Debbasch C, Brignole F, Pisella PJ et al (2001) Quaternary ammoniums and other preservatives‘ contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 42:642–652PubMed
14.
Zurück zum Zitat Dong JQ, Babusis DM, Welty DF et al (2004) Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 20:285–292PubMedCrossRef Dong JQ, Babusis DM, Welty DF et al (2004) Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 20:285–292PubMedCrossRef
15.
Zurück zum Zitat Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246:1593–1601PubMedCrossRef Erb C, Gast U, Schremmer D (2008) German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246:1593–1601PubMedCrossRef
16.
Zurück zum Zitat Gandolfi S, Paredes T, Goldberg I et al (2012) Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 22:34–44PubMedCrossRef Gandolfi S, Paredes T, Goldberg I et al (2012) Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol 22:34–44PubMedCrossRef
17.
Zurück zum Zitat Henry JC, Peace JH, Stewart JA et al (2008) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol 2:613–621PubMed Henry JC, Peace JH, Stewart JA et al (2008) Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol 2:613–621PubMed
18.
Zurück zum Zitat Herreras JM, Pastor JC, Calonge M et al (1992) Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99:1082–1088PubMed Herreras JM, Pastor JC, Calonge M et al (1992) Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 99:1082–1088PubMed
19.
Zurück zum Zitat Ichijima H, Petroll WM, Jester JV et al (1992) Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 11:221–225PubMed Ichijima H, Petroll WM, Jester JV et al (1992) Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 11:221–225PubMed
20.
Zurück zum Zitat Jaenen N, Baudouin C, Pouliquen P et al (2007) Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17:341–349PubMed Jaenen N, Baudouin C, Pouliquen P et al (2007) Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 17:341–349PubMed
21.
Zurück zum Zitat Jumblatt MM, Mckenzie RW, Jumblatt JE (1999) MUC5AC mucin is a component of the human precorneal tear film. Invest Ophthalmol Vis Sc 40:43–49 Jumblatt MM, Mckenzie RW, Jumblatt JE (1999) MUC5AC mucin is a component of the human precorneal tear film. Invest Ophthalmol Vis Sc 40:43–49
22.
Zurück zum Zitat Kahook MY, Noecker RJ (2008) Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 27:339–343PubMedCrossRef Kahook MY, Noecker RJ (2008) Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 27:339–343PubMedCrossRef
23.
Zurück zum Zitat Kitazawa Y, Smith P, Sasaki N et al (2011) Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye 25:1161–1169PubMedCrossRef Kitazawa Y, Smith P, Sasaki N et al (2011) Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye 25:1161–1169PubMedCrossRef
24.
Zurück zum Zitat Labbe A, Pauly A, Liang H et al (2006) Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 22:267–278PubMedCrossRef Labbe A, Pauly A, Liang H et al (2006) Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 22:267–278PubMedCrossRef
25.
Zurück zum Zitat Lewis RA, Katz GJ, Weiss MJ et al (2007) Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 16:98–103PubMedCrossRef Lewis RA, Katz GJ, Weiss MJ et al (2007) Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 16:98–103PubMedCrossRef
26.
Zurück zum Zitat Liang H, Baudouin C, Pauly A et al (2008) Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 92:1275–1282PubMedCrossRef Liang H, Baudouin C, Pauly A et al (2008) Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 92:1275–1282PubMedCrossRef
27.
Zurück zum Zitat Liang H, Brignole-Baudouin F, Pauly A et al (2011) Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 28:311–325PubMedCrossRef Liang H, Brignole-Baudouin F, Pauly A et al (2011) Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther 28:311–325PubMedCrossRef
28.
Zurück zum Zitat Mietz H, Niesen U, Krieglstein GK (1994) The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 232:561–565PubMedCrossRef Mietz H, Niesen U, Krieglstein GK (1994) The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 232:561–565PubMedCrossRef
29.
Zurück zum Zitat Mundorf T, Wilcox KA, Ousler GW 3rd et al (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20:329–336PubMedCrossRef Mundorf T, Wilcox KA, Ousler GW 3rd et al (2003) Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes. Adv Ther 20:329–336PubMedCrossRef
30.
Zurück zum Zitat Noecker RJ, Herrygers LA, Anwaruddin R (2004) Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490–496PubMedCrossRef Noecker RJ, Herrygers LA, Anwaruddin R (2004) Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23:490–496PubMedCrossRef
31.
Zurück zum Zitat Nuzzi R, Vercelli A, Finazzo C et al (1995) Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 233:154–162PubMedCrossRef Nuzzi R, Vercelli A, Finazzo C et al (1995) Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 233:154–162PubMedCrossRef
32.
Zurück zum Zitat Pisella P-J, Debbasch C, Hamard P et al (2004) Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45:1360–1368PubMedCrossRef Pisella P-J, Debbasch C, Hamard P et al (2004) Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 45:1360–1368PubMedCrossRef
33.
Zurück zum Zitat Rathore MS, Majumdar DK (2006) Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 7:57PubMedCrossRef Rathore MS, Majumdar DK (2006) Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS PharmSciTech 7:57PubMedCrossRef
34.
Zurück zum Zitat Romanowski EG, Mah FS, Kowalski RP et al (2008) Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis. J Ocul Pharmacol Ther 24:380–384PubMedCrossRef Romanowski EG, Mah FS, Kowalski RP et al (2008) Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis. J Ocul Pharmacol Ther 24:380–384PubMedCrossRef
35.
Zurück zum Zitat Ryan G Jr, Fain JM, Lovelace C et al (2011) Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmol 11:8PubMedCrossRef Ryan G Jr, Fain JM, Lovelace C et al (2011) Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmol 11:8PubMedCrossRef
36.
Zurück zum Zitat Sherwood MB, Grierson I, Millar L et al (1989) Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology 96:327–335PubMed Sherwood MB, Grierson I, Millar L et al (1989) Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology 96:327–335PubMed
37.
Zurück zum Zitat Steuhl KP, Knorr M, Frohn A et al (1991) Uber den Einfluss antiglaukomatöser Augentropfen auf die Zelldifferenzierung der Konjunktiva. Fortschr Ophthalmol 88:865–869PubMed Steuhl KP, Knorr M, Frohn A et al (1991) Uber den Einfluss antiglaukomatöser Augentropfen auf die Zelldifferenzierung der Konjunktiva. Fortschr Ophthalmol 88:865–869PubMed
38.
Zurück zum Zitat Xiong C, Chen D, Liu J et al (2008) a rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 49:1850–1856PubMedCrossRef Xiong C, Chen D, Liu J et al (2008) a rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci 49:1850–1856PubMedCrossRef
Metadaten
Titel
Morphologische Veränderungen durch Konservierungsmittel in Augentropfen
verfasst von
Dr. K.K. Huber-van der Velden
H. Thieme
M. Eichhorn
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Die Ophthalmologie / Ausgabe 11/2012
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-012-2639-3

Weitere Artikel der Ausgabe 11/2012

Der Ophthalmologe 11/2012 Zur Ausgabe

Mitteilungen der DOG

Mitteilungen der DOG

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.